Company Overview and News

0
SHREE CEMENT LIMITED - Updates

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
Broker's call: Shree Cement (Buy)

2018-07-10 thehindubusinessline
Shree Cement (SCL) gained 1.87 per cent on Tuesday after rising 3 per cent on Monday on the expectation of healthy traction ahead due to sustained demand improvement and visible realisation recovery.
HCLTECH 500387 IDEA HCTHY 532281 ICLQY 532822 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Shareholders meeting

2018-07-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-07-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Updates

2018-06-28 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
SHREE CEMENT LIMITED - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

24
Market Update: RIL top Nifty gainer, hits new record high; ICICI, Indigo up 1-2%, Infratel down 3%

2018-06-21 moneycontrol
The broader indices including the Nifty and the Sensex are trading on a positive note this Thursday morning with the Nifty up 7 points at 10,779 and the Sensex is trading higher by 31 points at 35,578.
SUZLON 500325 TCHQY 532514 532755 SHREECEM IGL 534816 SUEL RLNIY 524804 TATAPOWER APOLLOTYRE AYRQY 532667 TECHM BATAINDIA TATASTEEL TATLY 500180 500387 BHRYY AUROPHARMA GODREJIND RELIANCE 500470 532461 RIGD INFRATEL HDFCBANK INDIGO 517354 HVLQY 500877 IBN 539207 539448 ICICIBANK TTST PNJZY HDB 532174 ARBQY HAVELLS TPCL PNB 500400 500043 500164 MANPASAND

0
SHREE CEMENT LIMITED - Updates

2018-06-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500387 SHREECEM

0
Shree Cement plans to close United Cement deal by July

2018-06-10 livemint
Kolkata: Shree Cement Ltd, one of India’s top three cement makers, has budgeted for a capital expenditure of ₹3,500 crore in the current financial year, which includes ₹2,000 crore to be spent to conclude the acquisition of a United Arab Emirates-based (UAE) firm.
EMKAY 500387 532737 SHREECEM

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...